SWG
HZNP

Summit Wealth Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Summit Wealth Group’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-20
Closed -$2K – 233
2021
Q2 		$2K Hold
20
– – ﹤0.01% 174
2021
Q1 		$2K Buy
+20
New +$1.69K ﹤0.01% 155

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Summit Wealth Group's HZNP Position: Q3 2021 in Review

Summit Wealth Group sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2021, closing a stake of 20 shares — an estimated $2K sold.

Summit Wealth Group first reported a position in HZNP in Q1 2021 and held it in 2 quarters. The position peaked at $2K in Q2 2021. 572 funds tracked by Wall St. Rank hold HZNP as of Q3 2021.

  • Summit Wealth Group reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2021 after selling out during the quarter.
  • Summit Wealth Group sold 20 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2021, an estimated $2K.
  • Summit Wealth Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2021 and held it in 2 quarters.
  • Summit Wealth Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2K in Q2 2021.
  • 572 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2021.

Based on Summit Wealth Group's 13F filing for Q3 2021, filed 12 Nov 2021.